Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 41.50 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 26 27 Next > Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients July 05, 2024 Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... Via Benzinga FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss July 05, 2024 From Genentech Via Business Wire Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer July 04, 2024 From Genentech Via Business Wire AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway June 27, 2024 The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. Via Benzinga Exposures Product Safety Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case June 24, 2024 The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... Via Benzinga Topics Lawsuit Exposures Financial Legal Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments June 21, 2024 Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. Via Benzinga Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost June 21, 2024 How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging. Via InvestorPlace Exposures Product Safety FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy June 21, 2024 The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. Via Benzinga Exposures Product Safety Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END Via FinancialNewsMedia Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche June 19, 2024 The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. Via MarketBeat Exposures Product Safety Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma June 15, 2024 From Genentech Via Business Wire Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win June 11, 2024 An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. Via Investor's Business Daily Exposures Product Safety Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. Via Benzinga Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 From FN Media Group LLC Via GlobeNewswire Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk June 07, 2024 From Genentech Via Business Wire Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations June 06, 2024 Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. Via Benzinga 2 Cathie Wood Biotech Stocks That Could Be Worth the Risk May 29, 2024 You don't need to buy her picks, but it's worth understanding them. Via The Motley Fool FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation May 29, 2024 From Genentech Via Business Wire If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today May 26, 2024 What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised. Via The Motley Fool Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies May 23, 2024 U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq. Via Benzinga Topics Lawsuit Exposures Financial Legal This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan May 21, 2024 The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. Via Benzinga FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation May 21, 2024 From Genentech Via Business Wire Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate May 16, 2024 Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with... Via Benzinga Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity May 16, 2024 From Genentech Via Business Wire Can Ocugen Stock Keep Churning Higher? April 29, 2024 This tiny biotech caught fire in 2024. Can it sustain the momentum? Via The Motley Fool Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? April 24, 2024 HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... Via Benzinga Exposures Product Safety 2 Small-Cap Growth Stocks With Room To Run April 24, 2024 These two small-cap growth stocks could be ready to run. Via The Motley Fool FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer April 18, 2024 From Genentech Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 26 27 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.